Serum samples from 31 children р4 years old who were convalescing after meningococcal disease were used in a quantitative hybridization assay to establish antibody reactivity to 94 candidate meningococcal vaccine antigens. Genes encoding 22 of 23 strongly recognized proteins were found in у94% of the patients' meningococcal strains, and most were also widely prevalent in Neisseria lactamica and other commensal Neisseria species. Similar antibody reactivity was found in serum samples from healthy control children, suggesting that these antibodies arose from asymptomatic colonization. The 23rd protein, NadA, elicited strong reactivity solely in convalescent patients previously infected with a nadA + strain. nadA was not present in any of 29 diverse N. lactamica strains, suggesting that reactivity in these children arose from meningococcal infection.
or soon will be (serogroups A, W-135, and Y) available, but there is no prospect of a similar vaccine to prevent disease caused by serogroup B, because native serogroup B polysaccharide is not immunogenic in humans [3] . Alternative antigens under investigation for use in a vaccine against serogroup B strains include chemically modified capsular polysaccharide [4] , lipo-oligosaccharide [5] , and outer-membrane proteins (OMPs) in various formulations [6] . In the case of protein candidates, extensive antigenic variation has proved to be a major stumbling block. In an attempt to circumvent this, outer-membrane vesicle (OMV) vaccines containing the whole natural repertoire of OMPs have been used in attempts to control meningococcal infection in Norway and Cuba, and there is a proposal to deploy a similar vaccine in New Zealand [7] [8] [9] .
However, such OMV vaccines have suffered the general drawback that the immune response they elicit is primarily to the immunodominant and hypervariable serosubtyping antigen PorA, resulting in a non-crossprotective immunity [10] . The search for less-variable protective antigens has received new impetus with the determination of the genome sequence of the virulent serogroup B meningococcal strain MC58 [11] . Computational methods have been used to identify open-reading frames (ORFs) that may encode surface-exposed (or exported) proteins. Three hundred fifty such ORFs were recently successfully expressed and purified from Escherichia coli [12] . Antisera elicited in mice against these antigens were used to identify proteins that were indeed exposed on the bacterial surface and capable of eliciting bactericidal antibodies. Genes encoding a few of these proteins appear to be well conserved across a range of strains, suggesting that bactericidal antibodies directed against them would have broad specificity [12] . We report here the results of a study performed to complement these observations. By use of a quantitative dot-blotting method, a wide selection of the novel purified proteins was probed with serum samples collected from young children, first to identify those antigens strongly and consistently recognized by children convalescing after meningococcal disease and then to establish whether such reactivity was disease specific, rather than elicited by prior neisserial colonization.
MATERIALS AND METHODS
Materials and bacterial strains. Serum was prepared from blood obtained from patients convalescing after meningococcal disease 6-8 weeks after each patient had been discharged from St. Mary's Hospital (London, UK). Uninfected control serum was prepared from blood obtained from adult volunteers, from blood obtained from children during a hospital visit for treatment unrelated to infectious disease (our collection), or from blood obtained as part of a vaccine trial immediately before administration of the first dose of vaccine (gift from A. Pollard, University of Oxford, Oxford, UK). Serum samples from student volunteers known to be colonized with N. meningitidis strains had been obtained as part of an earlier study [13] (gift from D. Ala'Aldeen, University of Nottingham, Nottingham, UK).
Recombinant meningococcal proteins (from serogroup B N. meningitidis strains MC58 or 2996) used in the dot-blotting procedure were purified from E. coli by use of a poly-histidyl (His) tag or glutathione S-transferase (GST) fusion partner, as described elsewhere [12] . The GST sample used as a negative control was prepared in the same way. A commercial preparation of tetanus toxoid vaccine was used as a positive control on the blots. N. meningitidis strains isolated from patients were obtained from various hospitals in the United Kingdom or from S. Gray (HPA Meningococcal Reference Unit, Manchester, UK). They are described in table 1. Serogroup B N. meningitidis strains MC58 and 2996 were from our collection. A capsule-deficient mutant (2996DsiaD) and a capsule-and nadA-deficient mutant (2996DsiaDDnadA) of strain 2996 were generated in our laboratory by use of established methods [14] . Twenty-nine N. lactamica strains were either from our collection or a gift from M. Maiden (University of Oxford, Oxford, UK): L19, 620, 310, 005-24, 8206, 090-10, 0900251, 085-12, 088-05, 094-24, 014-24, 030-24, 028-12, 0085-12, 039-03, 012-12, 4408, 224, 4116, 10102m, 017-02, 06610, 020-06, 081-24, 057-08, 004-12, 016-24, 049-12, and 058-24. Isolates of other neisserial species were from our collection: N. flavescens 2830, N. subflava NRL30008, N. flava NRL30017, N. sicca M97-252086, N. polysaccharea 2834, N. mucosa 2833, and N. cinerea 2829. All Neisseria species were cultured on GC Agar (Difco) supplemented with 1% isovitalex at 37ЊC in a 5% CO 2 atmosphere.
Dot-blotting. Proteins were spotted onto a nitrocellulose membrane by use of a Bio-Dot 96-well microfiltration unit (BioRad). Each spot included 1 mg of recombinant protein (or tetanus toxoid). For probing, membranes were incubated for 1 h in blocking buffer (PBS containing 5% skimmed milk powder [Oxoid] and 0.1% Tween 20 [Sigma]) at room temperature and then overnight with 5 mL of test serum diluted in 10 mL of blocking buffer at 4ЊC. Membranes were then washed with PBS containing 0.1% Tween 20 and were incubated for 1 h at room temperature with an anti-human IgG, IgA, and IgM alkaline phosphatase-conjugated antibody (Sigma) diluted in blocking buffer. Results were visualized by use of a STORM 860 phosphoimager (Molecular Devices) after the addition of ECF substrate (Amersham). The intensity of each spot and that of the membrane background were determined by use of Image-Quant software (Molecular Devices). To normalize results between different membranes, each spot intensity was expressed in terms of the background intensity of its membrane. Data were compared statistically by use of a 2-tailed t test on logtransformed data, assuming unequal variance between groups.
Southern-blot hybridization. Approximately 0.5 mg of bacterial genomic DNA was digested with ClaI restriction enzyme (Roche), separated by agarose gel electrophoresis, and capillaryblotted onto Hybond N membrane (Amersham). Probes ∼1 kb in length were amplified from the central portion of each target gene (or the entire length of the gene, if smaller) from genomic DNA of N. meningitidis strain MC58, by use of a polymerase chain reaction digoxigenin-labeled probe synthesis kit (Roche). Membranes were probed at 37ЊC by use of DIG Easy Hyb (Roche), washed to a stringency of 0.5ϫ standard saline citrate (SSC) in 0.1% SDS at 68ЊC, and visualized by use of CDP-Star (Roche).
ELISA. Wells of ELISA plates (Microlon; Greiner) were coated overnight at 4ЊC with recombinant NadA, at a concentration of 2 mg/mL, in 0.1 mol/L carbonate buffer (pH 9.5). Reference wells were coated with a pool of human serum samples containing known concentrations of immunoglobulin (Human Serum Protein Calibrator; DakoCytomation) diluted in a 2-fold series in the same buffer. Wells were blocked with 1% skimmed milk powder (Oxoid) in PBS containing 0.05% Tween 20 (Sigma) for 1 h at room temperature and then were incubated with test serum samples diluted 1:50 in blocking buffer overnight at 4ЊC. Reference wells were incubated with blocking buffer alone. Plates were washed with PBS plus 0.05% Tween 20 and were incubated with a horseradish peroxidase-conjugated antibody against either human IgG, IgM, or IgA (DakoCytomation), also diluted in blocking buffer, for 1 h at room temperature. Plates were washed again, and antibody was detected with tetramethylbenzidine (Sigma), to measure absorbance at 450 nm. Concentrations of test antibody were calculated from a 4-parameter standard curve derived from the human immunoglobulin reference wells. Groups were compared statistically by use of a 2-tailed t test on log-transformed data, assuming unequal variance between groups. Isolation of NadA-specific antibody from a human IgG preparation. One hundred micrograms of either NadA (961c2) or bovine serum albumin (BSA) was immobilized on tosyl-activated Dynabeads (Dynatech), according to the manufacturer's instructions. Coated Dynabeads were washed with PBS and were incubated overnight with pooled normal adult human IgG (Octagam; Octapharma). They were then extensively washed with PBS, and an aliquot of the final wash buffer was kept for analysis. Any bound immunoglobulin was eluted with 0.1 mL of 0.1 mol/L glycine-HCl buffer (pH 3). After immediate adjustment of the pH of the eluate, to pH 7, with 1 mol/L Tris-Cl (pH 9), the eluate was dialyzed against PBS and concentrated by a factor of 10.
Detection of antibodies recognizing native NadA on live N. meningitidis.
N. meningitidis strains 2996DsiaD and 2996DsiaD DnadA were grown, at 37ЊC with shaking, to the early stationary phase in Mueller-Hinton broth (Difco) supplemented with 0.25% glucose and then were resuspended to in blocking buffer (PBS containing 1% BSA and A p 0.05 600 0.4% sodium azide). One hundred microliters of bacterial suspension was incubated with 10 mL of antibody sample for 2 h at 4ЊC, washed twice with blocking buffer, and incubated for 1 h at 4ЊC with a fluorescein isothiocyanate-conjugated antibody against human immunoglobulins (Jackson Laboratories). The bacteria were washed twice in blocking buffer again and were incubated in 200 mL of PBS containing 0.25% formal-dehyde overnight in the dark. The presence of antibody binding to the bacteria was detected by use of a FACScalibur flow cytometer (Becton Dickinson).
RESULTS

Probing recombinant proteins with convalescent-phase serum samples by dot-blotting.
A quantitative dot-blotting method was devised to probe a large number of recombinant novel proteins from N. meningitidis by use of small volumes of serum samples obtained from young children convalescing after meningococcal disease. Nitrocellulose membranes were prepared containing 94 novel proteins in a grid array. Twenty-nine of these proteins were present as GST fusions, 48 contained a His tag, 14 contained both a His and a GST moiety, and 3 possessed no fusion partner. Recombinant GST was included on each membrane as a negative control. An aliquot of tetanus toxoid vaccine was added as a positive control.
Convalescent-phase serum samples from 31 children (age, 0.2-4.0 years) who had been infected with a broad range of serogroup B or C strains and whose infecting meningococcal strains were available for study were used to probe the membranes (table 1). In general, after probing, we did not observe any systematic bias in spot intensity with regard to the age of the subjects, to the molecular mass of the target proteins, or to the nature of their fusion tags (data not shown). Twentyfive of the 94 antigens were consistently recognized by this group of serum samples, generating geometric mean intensities of more than twice that of the GST control spot (figure 1). These differences were highly significant ( , for all 25 P р .0002 antigens). These represented 23 meningococcal proteins, since 3 of them (961, 961c2, and 961cm) were variants of the same protein, NadA (NMB1994; see table 2 and data given below).
Prevalence of genes encoding the 23 proteins in strains of N. meningitidis responsible for patients' infections. Chromosomal DNA was prepared from the strains of N. meningitidis isolated from each of the 31 patients and probed by Southernblot hybridization for gene sequences encoding each of the 23 novel proteins identified in figure 1. Twenty-two of these proteins were present in у29 (у94%) of the 31 strains (table 2) . The exception, nmb1994 (encoding NadA), was present in only 14 (45%) of the 31 strains.
Comparison of antibody responses in convalescent and uninfected children. The strong reactivity to meningococcal proteins detected in convalescent-phase serum samples may have been elicited by infection, either as a primary response or as an anamnestic response reflecting prior bacterial carriage. Alternatively, it could have been present at a high level before disease. To test the hypothesis that antibodies to the 23 most strongly recognized proteins were elicited as the result of meningococcal disease, serum samples from 16 of the original convalescent patients (age, 0.2-3.5 years) and serum samples from 15 children uninfected with N. meningitidis (age, 0.44-1.75 years) were used in a second dot-blotting experiment to probe 46 of the 94 original proteins (data not shown). Fortyfive of the proteins-including 22 of the 23 most antigenic proteins described above-were, in fact, as strongly recognized by serum samples from uninfected children as they were by those from convalescent children. The strong antibody responses detected toward these antigens may not, therefore, have resulted solely from exposure to N. meningitidis during disease. The single exception was NadA, which was recognized significantly more strongly by convalescent patients than by control subjects (results are given in detail below).
Prevalence of genes encoding the 23 proteins in commensal Neisseria species. It has been suggested that resistance to meningococcal infection arises as a result of nasopharyngeal colonization, with common nonpathogenic neisserial species expressing cross-reactive antigens [15, 16] . The possibility that serum reactivity to the meningococcal proteins identified in figure 1 might have arisen in this way was explored by use of Figure 3 . Spot intensities generated by recombinant variants of NadA after the probing of dot-blots with serum samples from convalescent children and from uninfected control subjects. A, Intensities produced by serum samples from 31 patients, divided into those whose infecting strain was nadA Ϫ (छ) or nadA + (ࡗ). P values above pairs of data refer to their comparison using a 2-tailed t test on log-transformed data. B, Intensities produced by serum samples from 15 uninfected children (⅜) and 6 convalescent children infected with nadA Ϫ meningococci (छ). Horizontal bars denote geometric mean values in both graphs. The results for glutathione S-transferase (GST) purified in the same way and for tetanus toxoid (TT) were included as negative and positive controls, respectively. a collection of commensal Neisseria species. Because N. lactamica is the neisserial species most commonly isolated from the upper respiratory tract of young children [17, 18] , we used Southern-blot hybridization to probe a genetically diverse collection of 29 strains for DNA encoding each of the 23 proteins. The results indicated that genes encoding 21 of the proteins were present in N. lactamica: 17 of the genes were present in all 29 of 29 strains analyzed, 1 in 28 strains, 1 in 26 strains, 1 in 17 strains, and 1 in only 5 of the 29 strains (table 2) . Although minor differences in sequence could, of course, lead to important antigenic differences between proteins encoded by the different neisserial species, this result established the possibility that the antibodies detected against these proteins in both patients and uninfected children could have resulted from carriage of either N. meningitidis or N. lactamica.
Only the genes encoding antigens 685 and NadA were not detected in any of the N. lactamica strains. A collection of the less common commensal Neisseria species was examined for the presence of these genes. Southern-blot hybridization indicated that DNA encoding antigen 685 was not present in any of a set of single isolates of N. subflava, N. flava, N. sicca, N.  mucosa, N. polysaccharea, N. cinerea, and N. flavescens (data , IgA (B) , and IgM (C) in different subjects, as measured by ELISA against recombinant NadA. Serum samples were obtained from 10 uninfected children (1); 16 convalescent children infected by nadA Ϫ meningococci (2); 14 convalescent children infected by nadA + meningococci (3); 10 university students with established nasopharyngeal carriage of meningococci (4); and 14 randomly chosen healthy adults (5) . Horizontal bars denote geometric mean values. P values above denoted pairs of data refer to their comparison, performed by use of a 2-tailed t test on log-transformed data. not shown). nadA was detected only in the N. sicca and N. cinerea isolates. These results were consistent with a hypothesis that elevated antibody levels to antigens 685 and NadA, as observed in patients and uninfected children, probably resulted from exposure specifically to strains of N. meningitidis (although, in the case of NadA, exposure via rare commensals cannot be ruled out).
Further analysis of antibody responses to NadA. The vaccine potential of NadA, a putative meningococcal adhesin, has been under scrutiny recently [19] , and, for this reason, several variant forms of the protein had been included on the membranes 961, 961a, 961b, 961c2, and 961cm (figure 2). In view of the fact that the nadA gene was only present in 14 of 31 strains from patients (table 2), dot-blotting results obtained with convalescent-phase serum samples were reanalyzed according to the nadA genotype of the infecting strain. The results showed that serum samples from patients infected with nadA + strains contained significantly higher amounts of antibody to all 4 recombinant NadA variants retaining surface-expressed domains than did serum samples from patients infected with nadA Ϫ strains ( ; figure 3A ). (No difference was seen in P р .007 reactivity to 961b, a recombinant version of the protein comprising only the membrane anchor domain [ figure 2 ].) Reactivity in serum samples from children infected with nadA Ϫ strains was indistinguishable from control serum samples from healthy children ( ; figure 3B) . P 1 .05 These results were investigated further by use of an ELISA, in which we analyzed the anti-NadA IgG, IgM, and IgA antibody responses in serum samples from 10 uninfected children (age, 1.0-1.8 years), 16 convalescent patients infected with nadA Ϫ strains (age, 0.4-4.0 years), and 14 convalescent patients infected with nadA + N. meningitidis strains (age, 0.2-4.0 years). Two further sets of serum samples were also examined: 1 set from 14 healthy adults, and 1 set from 10 university students who were found, during a carriage study, to be chronically colonized with N. meningitidis. Analysis of anti-NadA IgG revealed that serum samples from patients infected with nadA + strains possessed significantly higher levels than samples from both patients infected with nadA Ϫ strains and uninfected control children ( figure 4A ). Of interest, anti-NadA IgG levels in this group were indistinguishable from levels in the serum samples from both healthy adults and students known to be colonized with meningococci ( and , respectively; P p .20 P p .30 figure 4A ). Similarly, patients infected with nadA + strains possessed significantly elevated levels of anti-NadA serum IgA, compared with both of the other groups of children ( figure  4B) . These levels were not statistically different from those in the colonized students but were not as high as those in the healthy adults ( and , respectively). In contrast, P p .11 P p .01 NadA-specific serum IgM levels were not significantly different between any of the 3 groups of children ( , for all com- parisons), and these levels were all significantly lower than those in both groups of adults ( figure 4C) .
To determine whether the NadA-specific IgG detected in human serum samples was capable of binding to native NadA on live meningococci, we isolated NadA-specific antibody from a commercial preparation of pooled normal adult IgG (Octagam) by use of immobilized recombinant NadA (961c2). As a control, the same procedure was performed with immobilized BSA. The presence of antibody in both a pre-elution wash (control for antibody carryover from original IgG sample) and low-pH eluate (releasing any bound antibody) from each immobilized target protein was analyzed by incubating them with live meningococci and detecting any bound antibody by use of flow cytometry. A capsule-deficient mutant of the meningococcal strain 2996 was used as the target, to maximize the sensitivity of the assay, and a nadA + version of the strain was compared with a nadA Ϫ mutant, to test the specificity of any antibody detected for NadA. The results showed that only the low-pH eluate from beads coated with NadA contained antibody that bound to the surface of live meningococci and that the antibodies were specific for NadA ( figure 5 ). Hence, naturally acquired anti-NadA IgG isolated from healthy adults is capable of targeting live meningococci.
DISCUSSION
We used a quantitative dot-blotting technique to probe a large number of recombinant meningococcal antigens with small volumes of serum from young children convalescing after meningococcal disease and from healthy control subjects. By this means, we determined that 23 of the 94 proteins examined with serum samples from 31 convalescent subjects were consistently reactive, eliciting signals of geometric mean intensity 2-6 times greater than that elicited by the GST control (figure 1). Some of these proteins had previously been established to have vaccine potential [12, [19] [20] [21] [22] , and others have been described here for the first time. It was encouraging that, although these children had been infected with genetically diverse strains of N. meningitidis, Southern blotting detected the genes encoding 22 of the 23 proteins almost universally in the infecting strains (the exception, NadA, is discussed below). Hence, the DNA analysis complements the results of the immunoblotting and implies a degree of conservation of genes encoding the 22 proteins across the meningococcal population.
Selecting serum samples from children convalescing after meningococcal disease offered the possibility of detecting bacterial antigens expressed specifically during systemic infection. However, when levels of antibody to these meningococcal proteins were compared with those in serum samples from uninfected children of a similar age, no differences were seen for 22 of the 23 antigenic proteins (NadA again was the exception).
This result suggested that these elevated antibody levels were not elicited exclusively by meningococcal disease.
Other than during an epidemic (when it has been reported at levels of the order of 2% in children !4 years old [17] ), nasopharyngeal carriage of N. meningitidis is generally accepted to be very unusual in infancy and rare before midchildhood [23, 24] . In contrast, young children are frequent carriers of N. lactamica, which has been reported to colonize up to 50% of children between the ages of 7 months and 3 years [17, 18, 25] . Because asymptomatic colonization with N. lactamica is sufficient to elicit an antimeningococcal serum antibody response [16, 18] , we investigated whether the specific serum antibodies detected in both the convalescent patients and the healthy control children could have resulted from exposure to N. lactamica strains. Examination of a collection of 29 genetically diverse N. lactamica strains (their diversity was established by multilocus sequence typing [M. Maiden, personal communication]), by Southern-blot hybridization using gene probes amplified from the N. meningitidis MC58 genome, revealed that 21 of the 22 genes were present in 5-29 of the 29 N. lactamica strains (table  2) . This result indicates that the reactivity seen in the serum samples from healthy children may have resulted from their colonization with N. lactamica during the first year of life. Indeed, formulations of proteins extracted from the N. lactamica outer envelope are regarded as holding corresponding promise as vaccines to prevent meningococcal disease [26] . Only 1 of the 22 genes, nmb1880 (encoding antigen 685, part of a putative iron transporter ATP-binding cassette-type enterochelin transport system) was absent from all the N. lactamica strains examined. It was not detected in any single strain of N. flava, N. subflava, N, sicca, N. mucosa, N. polysaccharea, N. cinerea, or N. flavescens (data not shown). We speculate that the reactivity of serum samples from healthy children to this protein resulted either from rare exposure to N. meningitidis strains (because it was present in all N. meningitidis strains tested) or from its sequence similarity to components of other iron-transport systems. For example, a component of another neisserial Fe(III) transporter (NMB1989) is a paralogue of NMB1880 (47% identity and 65% similarity) and also is present in all the infecting N. meningitidis strains, and there are highly homologous iron-transport systems in other bacteria commonly found in the infant gut.
Establishing the immunogenicity of these 22 proteins in children infected with a broad range of meningococcal strains is the first stage in making the case for considering their inclusion in a cross-protective meningococcal vaccine. The next stage will be to establish whether specific antibodies in healthy children are protective against meningococcal disease. It has not proved to be feasible to isolate antibodies against each of these proteins in our serum samples to measure bactericidal activity, because of the small volumes of serum at our disposal. Animal-protection studies have shown the potential vaccine efficacy of some of these proteins ( [12] and authors' unpublished data), but, in the end, only prospective trials of candidate vaccine antigens in humans can definitively resolve this issue.
NadA, the 23rd highly reactive protein detected in the present study, is a recently described meningococcal surface protein and is a putative adhesin that has been shown to elicit bactericidal antibodies in mice and to protect infant rats from experimental infection [19, 27] . Our dot-blotting and ELISA data (figures 3 and 4) suggest that IgG (and, to a lesser extent, IgA) antibodies to NadA are elicited by exposure to nadA + meningococcal strains through colonization or disease but are not generated during the course of colonization with common nonpathogenic Neisseria species that lack the gene, such as N. lactamica. Serum samples from the children studied here who had not had meningococcal disease or from those who had been infected with a nadA Ϫ strain lacked antibody, which is consis-tent with the low level of meningococcal colonization found in young children in the United Kingdom. However, serum samples from healthy adults, including 10 who were proven to be N. meningitidis carriers, were uniformly positive for anti-NadA IgG by ELISA, at levels equivalent to those found in children convalescing after infection ( figure 4 ). This result suggests that, outside the context of clinically apparent infection with a nadA + strain, anti-NadA antibody might generally result from carriage specifically of N. meningitidis, as occurs at increasing frequency in late childhood and early adulthood. Furthermore, our in vitro probing of nadA + and nadA Ϫ meningococci using NadA-specific antibody isolated from adult IgG confirmed that naturally occurring anti-NadA IgG is capable of binding to the native protein on live bacteria (a property recognized as a useful indication of functional activity [28] ). We chose to work with unencapsulated meningococci, to maximize our ability to detect antibody to this OMP. However, Comanducci et al. [19] have demonstrated that murine anti-NadA polyclonal antibodies can access native NadA on the bacterial surface beneath the polysaccharide capsule, albeit at lower efficiency than in capsule-deficient organisms. Taken together with those of animal studies, our results significantly advance the candidacy of NadA as a component of a vaccine to prevent meningococcal disease in infancy. There is, however, one important caveat. Although nadA has been acknowledged not to be present in all meningococcal strains, the gene was reported to be present in the majority of disease-associated isolates in Europe [19] and in Brazil [27] . In the present work, nadA was only found in a minority (14/31) of meningococcal strains responsible for invasive infection (table 1) . This result suggests that a meningococcal vaccine based solely on NadA would not provide adequate coverage in the United Kingdom, although this protein may form a valuable component of a multivalent formulation.
